As increased levels of Aβ42 is a major pathogenic factor in AD, understanding the cellular mechanisms by which IGF-1 and leptin interact to modulate Aβ42 effects may be relevant to the search of agents that preclude the deleterious effects of this peptide. This evidence concerns the gene LEP and Alzheimer disease.